8/7/2026

Thrombin Topical Solution (Bovine) and Powder (Recombinant)

Products Affected - Description

- Recothrom topical powder, Baxter, 20,000 unit kit, with spray pump spray bottle, syringe spray tip, syringe, bowl 1 count, NDC 00338-0330-01
- Recothrom topical powder, Baxter, 5,000 unit vial, with 5 mL prefilled diluent syringe plus 5 mL empty syringe 1 count, NDC 00338-0322-01
- Thrombin JMI, Pfizer, 20,000 unit, syringe spray kit, 1 count, NDC 60793-0217-22
- Thrombin JMI, Pfizer, 20,000 unit, pump spray kit, 1 count, NDC 60793-0217-21
- Thrombin JMI, Pfizer, 20,000 unit, vial, 1 count, NDC 60793-0217-20
- Thrombin JMI, Pfizer, 5,000 unit, Epistaxis kit, 1 count, NDC 60793-0205-05
- Thrombin JMI, Pfizer, 5,000 unit, syringe spray kit, 1 count, NDC 60793-0705-05
- Thrombin JMI, Pfizer, 5,000 unit, vial, 1 count, NDC 60793-0215-05

Reason for the Shortage

- Baxter has Recothrom on shortage due to a third-party supplier issue.
- Pfizer has Thrombin-JMI on shortage due to a third-party supply issue. Thrombin-JMI Liquid is expected to launch in 4th quarter 2026.

Available Products

- Recothrom topical powder, Baxter, 20,000 unit vial, with 20 mL prefilled diluent syringe plus 20 mL empty syringe 1 count, NDC 00338-0326-01

Estimated Resupply Dates

- Baxter has Recothrom 5,000 unit vials and 20,000 unit syringe spray kits in limited supply.
- Pfizer has Thrombin-JMI 5,000 unit epistaxis kits, 5,000 unit syringe spray kits, 5,000 unit vial kits, and 20,000 unit syringe spray kits on back order and the company estimates a release date of June 2027. The 20,000 unit pump spray kit are available in limited supply. The 20,000 unit vial kits are available in limited supply with weekly releases.

Updated

Updated August 7, 2026 by Michelle Wheeler, PharmD, Drug Information Specialist. Created February 23, 2022 by Leslie Jensen, PharmD, Drug Information Specialist. © 2026, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.